title: Ofloxacin versus cephalexin for treating skin and soft tissue infections.
abstract: Patients with acute localized skin or soft tissue infections were randomized to receive either ofloxacin (300 mg orally, b.i.d.) or cephalexin (500 mg orally, b.i.d.). Among 401 enrolled patients, 382 were evaluable for safety and 148 for microbiologic response. Microbiologic cure occurred in 93.4% of ofloxacin-treated patients and in 94.0% of those treated with cephalexin. Clinical cure or improvement, respectively, was found in 85.2% and 11.1% of patients treated with ofloxacin, and 83.6% and 14.9% of patients receiving cephalexin. Adverse effects (primarily associated with the gastrointestinal tract and central nervous system) were considered to be drug-related in 7.9% of those receiving ofloxacin and 4.8% of those receiving cephalexin. Thus, ofloxacin is as effective and well tolerated as cephalexin and a good alternate antibiotic for treating skin and skin structure infections caused by a variety of pathogens.
authors.affiliation: General Internal Medicine Clinic, Seattle VA Medical Center (111M), WA 98108.
authors.forename: B A
authors.initials: BA
authors.lastname: Lipsky
authors.forename: D R
authors.initials: DR
authors.lastname: Yarbrough
authors.forename: F B
authors.initials: FB
authors.lastname: Walker
authors.forename: R D
authors.initials: RD
authors.lastname: Powers
authors.forename: M R
authors.initials: MR
authors.lastname: Morman
mesh_terms: D002506:Cephalexin / Q000009:adverse effects / Q000627:therapeutic use*; D003240:Connective Tissue Diseases / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D015242:Ofloxacin; D002506:Cephalexin